Study of ARTS-021 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This study, the first clinical trial of ARTS-021, aims to determine the safety, tolerability,
pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of
ARTS-021 in patients with advanced solid tumors. ARTS-021 is an oral medication that inhibits
cyclin-dependent kinase 2 (CDK 2).